Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost its existing products and services.
Thermo Fisher's PPD arm unveils a new facility in Sweden, expanding its bioanalytical capabilities.
Thermo Fisher Scientific (NYSE:TMO ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 8:30 AM ET Company Participants Marc Casper - Chairman, President and CEO Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant Hey, everyone. Good morning.
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?
Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).
Thermo Fisher Scientific TMO recently secured FDA's 510(k) clearance for its SeCore CDx HLA A Sequencing System for use as a companion diagnostic (CDx) alongside Adaptimmune's ADAP newly approved T-cell receptor (TCR) therapy, TECELRA (afamitresgene autoleucel). The latter is the first engineered cell therapy for a solid tumor cancer approved in the United States and the first new therapy option in more than a decade for synovial sarcoma — a rare, soft tissue cancer that most commonly impacts young adults.
Thermo Fisher Scientific is a top dividend growth stock with a complex post-pandemic situation. Recent earnings show promising growth in key segments, despite a high valuation. Strategic investments in R&D and acquisitions position TMO for continued long-term success.
Given the expanding size of the nanotechnology industry, buying nanotechnology stocks with a very low-risk profile is possible. Electronics is one of the most important sectors that applies nanotechnology.
Thermo Fisher Scientific is finally starting to show signs of growth after getting through the headwind of declining covid-related business. Growth sources include increased business in China, completion of the Olink deal, and an increase in the number of clinical trials. Financial model updates and valuation analysis suggest the stock is currently priced at fair value, making it a Hold for now.
The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.
The headline numbers for Thermo Fisher (TMO) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Thermo Fisher Scientific (TMO) reported better second-quarter earnings than analysts had expected Wednesday, and also raised its projections for the full fiscal year.